Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium

Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1387-8. doi: 10.1007/s00417-007-0559-8. Epub 2007 Mar 7.

Abstract

Purpose: The purpose was to report a case of elevated intraocular vascular endothelial growth factor (VEGF) levels in a 2-year-old boy with stage 4 Coats disease.

Design: Interventional case report.

Methods: A 2-year-old boy with severe Coats disease and complex retinal detachment refractory to surgical intervention underwent two injections of intravitreal pegaptanib sodium in his right eye 8 weeks apart.

Results: After intravitreal injection there was a marked reduction in VEGF (908 to 167 pg/ml) levels and improvement of exudation, hemorrhage, and nearly complete reattachment of his retina within 3 weeks of treatment. The patient remains stable 6 months post-treatment.

Conclusions: Coats disease may have a component of dysregulation of VEGF-mediated angiogenesis as evidenced by elevated levels in this patient.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Aptamers, Nucleotide / therapeutic use*
  • Child, Preschool
  • Humans
  • Injections
  • Male
  • Retinal Diseases / drug therapy*
  • Retinal Diseases / metabolism
  • Retinal Vessels / drug effects*
  • Retinal Vessels / pathology
  • Telangiectasis / drug therapy*
  • Telangiectasis / metabolism
  • Vascular Endothelial Growth Factor A / metabolism*
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Aptamers, Nucleotide
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • pegaptanib